CC
TEVA icon

Clearline Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Clearline Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,098,786
Closed -$22.2M – 132
2025
Q3 		$22.2M Buy
1,098,786
+392,674
+56% +$6.9M 1.02% 15
2025
Q2 		$11.8M Buy
706,112
+222,090
+46% +$3.58M 0.44% 42
2025
Q1 		$7.44M Buy
+484,022
New +$8.65M 0.45% 45
2024
Q3 		– Sell
-336,849
Closed -$5.47M – 168
2024
Q2 		$5.47M Hold
336,849
– – 0.15% 65
2024
Q1 		$4.75M Sell
336,849
-678,717
-67% -$8.56M 0.23% 57
2023
Q4 		$10.6M Buy
1,015,566
+288,770
+40% +$2.7M 0.65% 28
2023
Q3 		$7.41M Sell
726,796
-334,485
-32% -$3.11M 0.64% 41
2023
Q2 		$7.99M Buy
+1,061,281
New +$8.61M 0.46% 31
2015
Q3 		– Sell
-90,670
Closed -$5.36M – 62
2015
Q2 		$5.36M Sell
90,670
-190,306
-68% -$11.7M 0.75% 33
2015
Q1 		$17.5M Hold
280,976
– – 2.62% 16
2014
Q4 		$16.2M Hold
280,976
– – 2.51% 17
2014
Q3 		$15.1M Hold
280,976
– – 2.43% 19
2014
Q2 		$14.7M Buy
280,976
+28,055
+11% +$1.43M 2.35% 12
2014
Q1 		$13.4M Buy
+252,921
New +$11.7M 3.04% 11

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Clearline Capital's TEVA Position: Q4 2025 in Review

Clearline Capital sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 1,098,786 shares — an estimated $22.2M sold.

Clearline Capital first reported a position in TEVA in Q1 2014 and held it in 14 quarters. The position peaked at $22.2M in Q3 2025. 631 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Clearline Capital reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Clearline Capital sold 1,098,786 Teva Pharmaceuticals shares in Q4 2025, an estimated $22.2M.
  • Clearline Capital first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 14 quarters.
  • Clearline Capital's Teva Pharmaceuticals position peaked at $22.2M in Q3 2025.
  • 631 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Clearline Capital's 13F filing for Q4 2025, filed 17 Feb 2026.